Holen Sie sich die Stockscreener-App
208.88
0.32%
0.52
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
What Is the Intent Behind AbbVie's Recent Acquisition Spree? - Zacks Investment Research
RINVOQ's Expansion into Giant Cell Arteritis: A Strategic Catalyst for AbbVie's Immunology Growth in Canada - AInvest
Pharma giant AbbVie to spend over US$1B on Gilgamesh’s lead psychedelic - Mugglehead Magazine
AbbVie Buys Bretisilocin from Gilgamesh in $1.2B Deal to Expand Depression Drug Pipeline–Another Win in the Psychedelic Space? - geneonline.com
AbbVie to Acquire Gilgamesh's Antidepressant Bretisilocin in $1.2 Billion Deal - PharmiWeb.com
Stock Analysis | Abbvie OutlookMixed Signals Amid Optimistic Analysts and Strong Fund Flows - AInvest
Healthcare Deals This Week: AbbVie, Royalty Pharma, BeOne - Law360
Using economic indicators to assess AbbVie Inc. potentialDividend Hike & Low Risk Growth Stock Ideas - Newser
AbbVie To Buy Gilgamesh Pharmaceuticals’ Bretisilocin Therapy - Pulse 2.0
Bullish Candlestick Pattern Forms in AbbVie Inc. getLinesFromResByArray error: size == 0 - 더경남뉴스
Risk adjusted return profile for AbbVie Inc. analyzed2025 Market Trends & Safe Swing Trade Setups - Newser
AbbVie to acquire Gilgamesh’s bretisilocin - The Pharma Letter
Alopecia Areata Market to Witness Dynamic Shift as AbbVie Reports Positive Topline Results from Phase III UP-AA Trial of RINVOQ | DelveInsight - Barchart.com
What recovery options are there for AbbVie Inc.Portfolio Update Report & Precise Buy Zone Identification - Newser
AbbVie to Acquire Investigational Therapy for $2.1B - Powder & Bulk Solids
AbbVie: Plenty Of Positives (NYSE:ABBV) - Seeking Alpha
Analyzing recovery setups for AbbVie Inc. investorsChart Signals & Stepwise Swing Trade Plans - Newser
What high frequency data says about AbbVie Inc.2025 Institutional Moves & Growth Focused Stock Pick Reports - Newser
As the Market Rotates, This Healthcare ETF Is Leading the Way - Investing.com
AbbVie Strikes $1.2 Billion Agreement For Next-Gen Psychedelic Depression Treatment - Benzinga
AbbVie’s (ABBV) Fell in Line with the Broader Biopharmaceutical Industry - Insider Monkey
AbbVie to Acquire Gilgamesh Pharmaceutical’s Psychedelic Drug for $1.2B - Contract Pharma
AbbVie dives back into the neuro pool with a $1.2B psychedelics play - PharmaVoice
ABBV Buys Rights to Bretisilocin, a Novel Psychedelic for Depression - Yahoo Finance
AbbVie signs to acquire Gilgamesh’s bretisilocin for $1.2bn - Pharmaceutical Technology
Key metrics from AbbVie Inc.’s quarterly data2025 Analyst Calls & Weekly High Momentum Picks - Newser
AbbVie Places $1.2 Billion Bet on Next-Generation “Non-Hallucinogenic” Psychedelic Drug - NAI500
Does AbbVie Inc. show high probability of reboundQuarterly Earnings Summary & Free Weekly Watchlist of Top Performers - Newser
How To Put $100 In Your Retirement Fund Each Month With AbbVie Stock - Yahoo Finance
AbbVie to Acquire Gilgamesh's Experimental Antidepressant for $12 Billion - AInvest
AbbVie Acquires Gilgamesh’s Psychedelic MDD Program For Up To $1.2B - HIT Consultant
AbbVie's latest acquisition targets Gilgamesh's psychedelic drug to treat depression - The Business Journals
AbbVie Buys Phase II MDD Candidate From Gilgamesh, But Not The Company - insights.citeline.com
AbbVie Inc. stock underperforms Monday when compared to competitors - MarketWatch
AbbVie to Acquire Gilgamesh’s Bretisilocin in $1.2B Psychedelic Bet - USA Herald
AbbVie Nabs Depression Drug From Gilgamesh In $1.2B Deal - Law360
AbbVie Expands Psychiatry Drug Pipeline with Acquisition of Gilgamesh Pharmaceuticals’ Bretisilocin for Major Depressive Disorder - Pharmaceutical Executive
Atai Life Sciences stock surges on AbbVie’s psychedelic drug acquisition - Investing.com
AbbVie to acquire Gilgamesh Pharma’s depression drug for up to $1.2 billion - Latest news from Azerbaijan
AbbVie to Buy Experimental Depression Drug From Gilgamesh For up to $1.2 Billion - MarketScreener
AbbVie targets psychedelic-based depression drug market with $1.2 billion deal - Reuters
AbbVie wagers more than $1B on Gilgamesh’s psychedelic drug - BioPharma Dive
Unswayed by Cerevel Failure, AbbVie Buys Gilgamesh’s Depression Drug for $1.2B - BioSpace
AbbVie makes $1.2B deal to buy Gilgamesh's psychedelic drug candidate - Crain's Chicago Business
Gilgamesh joins a second $1B+ deal with Abbvie - BioWorld MedTech
AbbVie to buy psychedelic drug from partner Gilgamesh - Endpoints News
AbbVie to Buy Gilgamesh Depression Drug for Up to $1.2 Billion - Bloomberg
AbbVie to Acquire Gilgamesh’s Bretisilocin for Up to $1.2B - Psychedelic Alpha
AbbVie to buy Gilgamesh’s psychedelic drug for up to $1.2 billion - statnews.com
AbbVie to buy Gilgamesh drug in $1.2B deal - Axios
AbbVie to buy Gilgamesh Pharma's depression drug for up to $1.2 billion - Reuters
AbbVie's Strategic Position in the Biotech Sector Amid a Shifting R&D Landscape - AInvest
AbbVie to acquire Gilgamesh’s depression drug bretisilocin for $1.2 billion - Investing.com
AbbVie to buy Gilgamesh’s depression program for up to $1.2B (ABBV:NYSE) - Seeking Alpha
AbbVie Is A Top Biotech Pick (NYSE:ABBV) - Seeking Alpha
Abbvie to acquire Gilgamesh Pharmaceuticals' Bretisilocin - MarketScreener
21.6-Point Depression Score Improvement: AbbVie Acquires Breakthrough Short-Acting Psychedelic Drug - Stock Titan
AbbVie Seeks To Expand Psychiatry Pipeline By Acquiring Gilgamesh’s Lead Candidate For Up To $1.2B - Stocktwits
AbbVie Inc. (ABBV) Stock Analysis: Unveiling Growth Potential With A 3.11% Dividend Yield - DirectorsTalk Interviews
How to escape a deep drawdown in AbbVie Inc.Market Growth Summary & Community Consensus Trade Signals - Newser
Visual analytics tools that track AbbVie Inc. performance2025 Major Catalysts & Safe Capital Growth Trade Ideas - Newser
AbbVie’s Promising Phase 3 Study on Upadacitinib for Hidradenitis Suppurativa - TipRanks
AbbVie’s Promising CLL Study: A Potential Game-Changer for Investors - TipRanks
Will AbbVie Inc. benefit from macro trendsVolume Spike & Community Verified Swing Trade Signals - Newser
AbbVie Investors Beware: Strong Growth Potential, Rising Risks (NYSE:ABBV) - Seeking Alpha
ABBV's Improving Oncology Sales Poise It Well for Long-Term Growth - The Globe and Mail
AbbVie Pins Hopes on Rinvoq to Drive Next Phase of Growth - Yahoo Finance
0.33%
0.99%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):